論文

2021年10月1日

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer

PLOS ONE
  • Shunsuke Tsuzuki
  • ,
  • Shotaro Nakanishi
  • ,
  • Mitsuyoshi Tamaki
  • ,
  • Takuma Oshiro
  • ,
  • Jun Miki
  • ,
  • Hiroki Yamada
  • ,
  • Tatsuya Shimomura
  • ,
  • Takahiro Kimura
  • ,
  • Nozomu Furuta
  • ,
  • Seiichi Saito
  • ,
  • Shin Egawa

16
10
開始ページ
e0258160
終了ページ
e0258160
記述言語
掲載種別
研究論文(学術雑誌)
DOI
10.1371/journal.pone.0258160
出版者・発行元
Public Library of Science (PLoS)

<sec id="sec001">
<title>Background</title>
There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).


</sec>
<sec id="sec002">
<title>Methods</title>
The clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared.


</sec>
<sec id="sec003">
<title>Results</title>
190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the standard and the reduced dose group. In the PSM cohort, the PSA response rate was significantly lower in the reduced dose group than in the standard dose group (-66.3% and -87.4%, p = 0.02). The incidence rates of AEs were not statistically different between the groups (22.6% and 34.4%, respectively, p = 0.24).


</sec>
<sec id="sec004">
<title>Conclusion</title>
Initiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs.


</sec>

リンク情報
DOI
https://doi.org/10.1371/journal.pone.0258160
URL
https://dx.plos.org/10.1371/journal.pone.0258160
ID情報
  • DOI : 10.1371/journal.pone.0258160
  • eISSN : 1932-6203

エクスポート
BibTeX RIS